(en) Nicholas L Syn, Michele W L Teng, Tony S K Mok et Ross A Soo, « De-novo and acquired resistance to immune checkpoint targeting », The Lancet Oncology, vol. 18, no 12, , e731–e741 (PMID29208439, DOI10.1016/s1470-2045(17)30607-1)
(en) Ishida Y, Agata Y, Shibahara K, Honjo T, « Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death », The EMBO Journal, vol. 11, no 11, , p. 3887–3895 (PMID1396582, DOI10.1002/j.1460-2075.1992.tb05481.x).
(en) Bardhan K, Anagnostou T, Boussiotis VA, « The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation », Frontiers in Immunology, vol. 7, , p. 550 (PMID28018338, PMCID5149523, DOI10.3389/fimmu.2016.00550).
(en) Nicholas L Syn, Michele W L Teng, Tony S K Mok et Ross A Soo, « De-novo and acquired resistance to immune checkpoint targeting », The Lancet Oncology, vol. 18, no 12, , e731–e741 (PMID29208439, DOI10.1016/s1470-2045(17)30607-1)
(en) Ishida Y, Agata Y, Shibahara K, Honjo T, « Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death », The EMBO Journal, vol. 11, no 11, , p. 3887–3895 (PMID1396582, DOI10.1002/j.1460-2075.1992.tb05481.x).
(en) Bardhan K, Anagnostou T, Boussiotis VA, « The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation », Frontiers in Immunology, vol. 7, , p. 550 (PMID28018338, PMCID5149523, DOI10.3389/fimmu.2016.00550).